# Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05096663/  
OnCo record `nct05096663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of dexamethasone, docetaxel, gemcitabine, pembrolizumab and other drugs in lung cancer, run by SWOG Cancer Research Network, active but no longer recruiting.

## Summary

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is a phase 2/3, randomised interventional study registered as NCT05096663 by SWOG Cancer Research Network, with a registry enrolment figure of 82 participants, started 2022-03-15 and due to reach its primary completion in 2027-06-30. Interventions recorded: Cobalamin; Dexamethasone; Docetaxel; Folic Acid; Gemcitabine; Nogapendekin Alfa; Pembrolizumab; Pemetrexed; Ramucirumab. Conditions listed: Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lu. Primary outcome: Overall survival. Lung eligibility wording from the registry: "Assignment to S1800D is determined by the LUNGMAP or S1400 protocol". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05096663
- Phase: 2/3
- Setting: A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
- Sponsor: SWOG Cancer Research Network
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT05096663: https://clinicaltrials.gov/study/NCT05096663

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05096663.json